Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Innovator-of-Year to AMPEL
COMPANY
Leveraging RNA Analytics and AI to Deliver Personalized, Effective Treatments for Complex Conditions
At the 2024 Precision Health Summit, Amrie Grammer, Founder, President, and Chief Scientific Officer of AMPEL Biosolutions, presents a vision of how precision medicine can reshape autoimmune and inflammatory disease treatment.
Translating Discoveries into a Precision Health Business
Dr. Grammer is a Biotech Executive and NIH-trained Scientist-Entrepreneur (Immunology, Genomics, Pharmacology, ML/PredictiveAI) who has successfully translated her discoveries into a precision health business with prognostic tests for patients and monitoring biomarkers for pharma.
AMPEL BioSolutions Selected as Member of ARPA-H Customer Experience Hub Spoke Network
AMPEL’s ARPA-H spoke election highlights one-of-a-kind Precision Health tests that predict inflammation and abnormal drug targets from gene expression utilizing “explainable AI” (xAI). Other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs.
Innovator-of-Year to AMPEL
CBIC of Virginia honored the team with “Innovator-of-the-Year” last night June 1st for the AMPEL Genomic Platform of RNA analytics and Machine Learning for dynamic disease management through flare prediction & personalized decision support for drug options. Charlottesville Business Innovation Council (CBIC) presented AMPEL’s “Innovator-of-the-Year” award at the University of Virginia Research Park.
Virginia Workforce Award to AMPEL BioSolutions
Virginia officials recognized AMPEL BioSolutions for their dedication to identifying, training, and retaining STEM-trained workers, especially in the area of precision medicine. The annual award recognizes Virginia employers who provide high-quality internships to students.
From Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions, Joins BioTalk
Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL’s remarkable success in precision medicine, making this episode a must-listen.
PLATFORM
RNA-Based Precision Health: AMPEL’s Blood & Biopsy Tests
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares from a Blood Sample
AMPEL’s Genomic Platform: A Physician’s POV
Cville Company Uses Genetics and Big Data to Find Better Medical Treatments
Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show. Now, however, a Virginia company is taking a different approach – looking at drugs that already have FDA approval to see what other conditions they might treat.
AMPEL BioSolutions Latest Innovation in Precision Medicine Predicts Drug Options Using RNA Analytics and Machine Learning
A breakthrough in precision and customized medicine, announced by AMPEL BioSolutions, may update how physicians treat patients with various illnesses, including cancer, infectious disorders, and autoimmune.
PRODUCTS
Monitoring Lupus with Data: a discussion with Dr. Schneider(Stanford) & Dr. Grammer (AMPEL’s LuGENE Flare Blood Test)
AMPEL develops a blood test for cardiovascular disease
Armie Grammer, AMPEL’s co-founder, president, and chief scientific officer of AMPEL BioSolutions, explains the company’s CardioGENE blood test for cardiovascular disease risk.
New Blood Test Can Predict Heart Disease and Guide Prophylactic Treatment
AMPEL BioSolutions’ new CardioGENE blood test predicts heart disease by identifying genetic markers and inflammatory pathways, enabling personalized, preventive therapies.
Precision Medicine Blood Test Predicts Heart Disease Before It Occurs
A precision medicine blood test can predict heart disease before it happens and provide decision support for prophylactic therapies.
AMPEL BioSolutions: Precision Medicine Blood Testing Predicts Heart Disease and Therapeutic Intervention
AMPEL BioSolutions announced a precision medicine blood test that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Transforming Digital Health with Genomic Data and AI
In this seminar we will explore the cutting-edge intersection of AI and genomics that is reshaping the landscape of healthcare.
PARTNERS
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
The question that today’s publication addresses with the multicenter, randomized, double-blind, placebo-controlled ORKIDS trial was whether inflammatory disease activity of people living with Lupus was influenced with a “food as medicine” approach of Omega3 Krill Oil supplementation.
AMPEL BioSolutions: Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
The results indicate that Lupus patients have suboptimal omega-3 (measured in red blood cell membranes using the standard omega3 index) which was normalized by one month supplementation with Krill Oil.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients.
Wellness Approach with Lupus & Krill Oil
CLICK FOR ORIGINAL FACEBOOK POST > "Very Interesting. Please Read! Another Lupus Breakthrough!! Wellness Approach to Lupus w/KrillOil Disease activity of #Lupus decreased in a trial of 20sites across the #usa-#canada with Ampel Biosolutions Aker BioMarine ASA-Lupus...
Study Shows Krill Oil Improves Omega-3 Deficiency in Lupus Patients with Early Signs of Lessening Disease Activity in Patients with Severe Lupus
Increasing Omega-3 Index to an optimal level through krill oil supplementation may show benefit for this population and warrants further study.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Dr. Peter Lipsky, AMPEL BioSolutions’ Co-Founder, CEO and Chief Medical Officer, “The ORKIDS clinical trial of Krill Oil supplementation for Lupus was a team effort that documented patients were uniformly omega-3 fatty acid deficient which was reversible with Krill Oil supplementation.